摘要
目的:评价溴夫定125mg每天1次联合匹多莫德800mg每天1次治疗带状疱疹的疗效及预后情况。方法:多中心、随机、双盲、平行对照临床试验。236例带状疱疹患者分别接受溴夫定125mg每天1次联合匹多莫德800mg每天1次(117例)或溴夫定125mg每天1次(119例)治疗,疗程14d,再随访1个月。结果:止疱时间,试验组平均为3.9d,对照组为3.6d,两组比较,差异无统计学意义。消疱时间、疼痛缓解时间和疼痛消失时间两组比较,差异有统计学意义。试验组有8.9%、对照组有29.4%的患者皮损痊愈后仍存在疱疹相关疼痛。药物相关不良反应发生率分别为0.8%和5.0%。结论:溴夫定125mg每天1次联合匹多莫德800mg每天1次与溴夫定125mg每天1次相比,治疗带状疱疹更加有效、安全,疱疹后遗神经痛发生率低。
Objective：To assess efficacy of oral brivudine 125 mg once daily combined with pidotimod 800mg once daily versus brivudine 125 mg once daily in the treatment of herpes zoster.Methods：A five-centre,randomized,double-blind,paralle1controlled study was performed on 226 patients with herpes zoster.Oral brivudine 125 mg combined with pidotimod 800mg were given once daily to 117 patients,and Brivudine 125 mg once daily to 119 patients,both for 14 days.All patients were followed up for 1 month after the end of treatment.Results：The time to the last formation of new vesicles was 3.9 days for the test group,and 3.6 days for the control group,without significant diferences between the two groups.There was significant diference between the two groups with respect to the time of total resolution of vesicles,time to first relief of pain.and time to complete relief of pain.Postherpetic neuralgia occurred in 8.9% of patients in the test group.And 29.4% of patients in the control group.The incidence of treatment-related adverse events was 0.8% and 5.0%,in the test group and control group,respectively.Conclusion：Brivudine 125 mg once daily combined with pidotimod 800mg once daily is more effective,safer and lower postherpetic neuralgia occurrence in comparison with brivudine 125 mg once daily for the treatment of herpes zoster.
出处
《黑龙江医药》
CAS
2010年第4期554-556,共3页
Heilongjiang Medicine journal
关键词
溴夫定
匹多莫德
带状疱疹
随机对照试验
Brivudine
Pidotimod
Herpes zoster
Randomized controlled trials
